Hugin-News: Micromet Inc.

Corporate news- Mitteilung verarbeitet und übermittelt durch Hugin. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. ---------------------------------------------------------------------- --------------    

   Interim data from Phase 1b Study indicate that adecatumumab in combination with docetaxel is safe and well tolerated and suggest a better outcome for breast cancer patients with high EpCAM expression

BETHESDA, MD - September 15, 2008 -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company  developing novel,  proprietary  antibodies for the treatment  of cancer, inflammation  and autoimmune  diseases, presented interim  data from  a  study investigating  its  anti-EpCAM antibody   adecatumumab    (MT201)    in   combination    with    the chemotherapeutic docetaxel[1] on Saturday,  September 13 at the  2008 meeting of the European  Society of Medical  Oncology (ESMO) held  in Stockholm, Sweden.

Adecatumumab is an antibody that targets EpCAM, a tumor antigen known to be  associated  with poor  prognosis  for many  solid  cancers.  A previous phase 2 trial investigating  adecatumumab as a single  agent in patients  with  metastatic  breast  cancer  (MBC)  suggested  that treatment with adecatumumab was associated with fewer new  metastases in patients with high EpCAM expression compared to patients with  low EpCAM expression[2].

The ongoing phase  1b clinical trial  presented at ESMO  investigated the safety and  tolerability of increasing  doses of adecatumumab  in combination with  standard  chemotherapy docetaxel  in  relapsed  MBC patients who  had  a median  of  three prior  chemotherapy  regimens. Combining adecatumumab  with docetaxel  appears to  be feasible  with clinically manageable  diarrhea being  the  main toxicity  at  higher doses. Other  frequently  observed adverse  events  included  nausea, vomiting, stomatitis,  constipation, fatigue,  fever and  chills.  No increase in adverse events or laboratory abnormalities typically seen with docetaxel was observed.

The overall response rate according to RECIST has been reported to be 43 percent in patients with high  expression of EpCAM, the target  of adecatumumab (3 of 7 patients), whereas no responses were detected in patients with low EpCAM expression (0 of 8 patients).

"These  data  demonstrate  that   adding  adecatumumab  to   standard chemotherapy is  feasible  and  suggest  that  the  combination  with taxanes could be a valuable  treatment option for patients with  high EpCAM expression," said Carsten  Reinhardt, M.D., Ph.D., senior  vice president and chief medical  officer for Micromet.  "The trend for  a better outcome in patients  with high EpCAM  expression levels is  in line with earlier observations and  suggests a truly targeted  effect of adecatumumab against EpCAM-positive tumor cells."

In addition to  the continued clinical  development in patients  with breast cancer,  Micromet is  also  in the  process  of setting  up  a randomized  phase  2  clinical  trial  in  patients  suffering   from colorectal cancer  (CRC)  after  complete resection  of  first  liver metastases.

[1] First results from  a Phase 1b study  of the anti-EpCAM  antibody adecatumumab (MT201) in combination  with docetaxel in patients  with metastatic breast cancer.  M. Schuler et  al. ESMO Meeting  Abstract, Sep 2008; Abstract 485P.

[2] Highly reduced incidence of  new breast cancer metastases  during treatment with adecatumumab appears to be the major factor for longer time  to  tumor  progression   in  patients  with  high-level   EpCAM expression Ch. Dittrich et al. AACR Meeting Abstract, Oct 2007; A71.

About ESMO

The European  Society  for Medical  Oncology  (ESMO) is  the  leading European non-profit professional  organization for medical  oncology, with a focus on promoting  multidisciplinary cancer treatment  around the world.

Since its  founding  in  1975, ESMO  has  continuously  expanded  its mission, aiming to create a wider community of people involved in the multifaceted  aspects   and  phases   of  cancer:   a  community   of professionals who share the common goal of providing optimal care  to all cancer patients.

Through the years, the Society has strived to meet the needs of  both oncologists and patients. For oncology professionals, ESMO serves and offers support to its members in their daily practice and careers  by sharing knowledge and  expertise through  scientific and  educational activities.  For  patients,   ESMO  partners   with  cancer   patient associations and

(more)                                          Page 2 of 5

groups, by promoting direct and pro-active involvement of patients in educational, political, and networking activities. For the benefit of both, professionals and patients, in 2006 ESMO became active at the political level in order to  influence issues which could impact the oncology community.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical  company developing novel, proprietary antibodies for the treatment of cancer, inflammation and  autoimmune diseases.  Four  of its  antibodies  are currently in  clinical trials,  while the  remainder of  the  product pipeline  is   in  preclinical   development.  The   BiTE®   antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for  the treatment of  patients with  acute lymphoblastic  leukemia and  in  a phase  1  clinical   trial  for  the   treatment  of  patients   with non-Hodgkin's lymphoma.  BiTE antibodies  represent  a new  class  of antibodies  that  activate  a   patient's  own  cytotoxic  T   cells, considered the  most  powerful "killer  cells"  of the  human  immune system,  to   eliminate   cancer  cells.   Micromet   is   developing blinatumomab in collaboration with  MedImmune, Inc., a subsidiary  of AstraZeneca plc.  MT110  is  the second  BiTE  antibody  in  clinical trials, and is  being developed  by Micromet  in a  phase 1  clinical trial for the  treatment of  patients with  lung or  gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a  human monoclonal antibody  that targets epithelial  cell adhesion  molecule  (EpCAM)-expressing  solid  tumors.  Micromet   is developing adecatumumab in collaboration with Merck Serono in a phase 1b  clinical  trial  evaluating  adecatumumab  in  combination   with docetaxel for  the  treatment  of  patients  with  metastatic  breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is  being developed in a phase  1 clinical trial  for  the treatment  of  patients with  cancer.  Three additional  BiTE   antibodies,   targeting  CD33,   CEA   and   MCSP, respectively, are in preclinical  development. In addition,  Micromet has established a collaboration with Nycomed for the development  and commercialization  of  MT203,  a  human  antibody  neutralizing   the activity  of   granulocyte/macrophage   colony   stimulating   factor (GM-CSF), which  has  potential  applications  in  the  treatment  of various inflammatory  and  autoimmune diseases,  such  as  rheumatoid arthritis, psoriasis, or multiple sclerosis.

(more)                                               Page 3 of 5

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and  uncertainties  that  could  cause  actual  results  to  be materially different  from  historical  results or  from  any  future results expressed  or  implied by  such  forward-looking  statements. These forward-looking  statements  include statements  regarding  the efficacy, safety and intended utilization of our product  candidates, the development of our BiTE antibody technology, the conduct,  timing and results of  future clinical  trials, expectations  of the  future expansion of our product pipeline  and collaborations, and our  plans regarding future presentations  of clinical  data. You  are urged  to consider statements that include the words "ongoing," "may,"  "will," "believes,"   "potential,"    "expects,"   "plans,"    "anticipates," "intends," or the negative of those  words or other similar words  to be uncertain  and  forward-looking.  Factors that  may  cause  actual results to differ  materially from  any future  results expressed  or implied by  any  forward-looking  statements include  the  risk  that product  candidates  that  appeared  promising  in  early   research, preclinical studies  or clinical  trials  do not  demonstrate  safety and/or  efficacy  in  subsequent  clinical  trials,  the  risk   that encouraging results  from  early  research,  preclinical  studies  or clinical trials may  not be  confirmed upon further  analysis of  the detailed results  of such  research,  preclinical study  or  clinical trial, the risk that additional  information relating to the  safety, efficacy or tolerability of our product candidates may be  discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will  not obtain approval to market  our product candidates,  the risks  associated with  reliance on  outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono,  TRACON and Nycomed, for the  funding or conduct  of further development  and commercialization activities  relating  to  our  product  candidates. These factors  and  others are  more  fully discussed  in  Micromet's Annual Report on  Form 10-K for  the fiscal year  ended December  31, 2007, filed with the SEC on March 14, 2008, as well as other  filings by the company with the SEC.

Any forward-looking statements  are made pursuant  to Section 27A  of the Securities  Act of  1933,  as amended,  and  Section 21E  of  the Securities Exchange Act of 1934, as amended, and, as such, speak only as of  the date  made.  Micromet, Inc.  undertakes no  obligation  to publicly update any forward-looking  statements, whether as a  result of new information, future events or otherwise.

                                # # #

Contact Information

US Media:                                 European Media: Andrea tenBroek/Chris Stamm               Ludger Wess (781)-684-0770                            +49 (40) 8816 5964 micromet@schwartz-pr.com                  ludger@akampion.com

US Investors:                             European Investors: Susan Noonan                              Ines-Regina Buth (212) 966-3650                            +49 (30) 2363 2768 susan@sanoonan.com                        ines@akampion.com

--- Ende der Mitteilung  ---

Micromet Inc. Staffelseestr. 2 München Deutschland

WKN: A0JMQD; ISIN: US59509C1053; Notiert: Xetra Stars in Frankfurter Wertpapierbörse;

http://www.micromet.de

Copyright © Hugin AS 2008. All rights reserved.